跳至主要内容
临床试验/NCT02845440
NCT02845440已完成不适用

Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 1,165 人开始时间: 2016年7月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,165
试验地点
2
主要终点
Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohort 1

研究概览

简要总结

The overall aim of this study is to test the effect of academic detailing (i.e. provider-level educational intervention focused on evidence-based smoking cessation treatment for those with psychiatric illness) and community health worker (CHW) support on the provision and utilization of standard of care smoking cessation treatment to those with serious mental illness (SMI) and smoking cessation rates for adults with SMI who smoke.

详细描述

In this study, the investigators aim to test whether a provider-level educational intervention in the form of targeted, practical, action-oriented education to primary care physicians and nurses on safety and effectiveness of and how to use evidence-based smoking cessation treatment for those with psychiatric illness, termed academic detailing (AD), and practical support offered to the primary care physician / primary care team and the smoker with SMI in the form of a community health worker (CHW) will improve recommendation and utilization of standard of care smoking cessation treatments to and by those with SMI and, if so, whether the intervention improves smoking cessation rates for adults with SMI who smoke.

To do so, the investigators will enroll approximately 1300 adult smokers with SMI who receive psychiatric rehabilitation services, Community Based Flexible Support (CBFS) or Assertive Community Treatment (ACT)), from the two largest providers of these services in the Boston area. Primary care clinics that serve 3 or more enrolled participants will be cluster randomized in a 2:1 ratio to either receive AD for their clinical staff or treatment as usual (TAU) in a cluster randomized design. Smokers with SMI in the study who receive primary care at the clinics assigned to the AD intervention to providers will be randomly assigned at the individual level in a 1:1 ratio to be offered CHW support in addition to their ongoing psychiatric rehabilitation (CBFS or ACT) services. This was the original design for the study and these participants comprise Cohort 1. The protocol was modified and approved by the sponsor in February 2018 to include a second cohort. Because 155 enrolled participants received primary care in 155 clinics that served only 1-2 participants, and it was beyond the scope of the trial to deliver AD to so many clinics, a second cohort was formed in which these 155 participants were randomly assigned at the individual level in a 1:1 ratio to CHW or TAU.

This study was also modified by receipt of a qualitative supplement award from the sponsor to conduct mixed methods research to identify and define barriers and facilitators to implementation of components of the integrated care intervention in primary care clinical settings using an interactive convergent mixed-methods design. The aim of this portion of the study is to better understand the factors that impact the integration of Integrated Care and evidence-based treatments for smoking cessation for those with SMI in primary care settings. Qualitative interviews will be conducted for enrolled participants, CHWs, primary care physician, and stakeholders.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohort 1

时间窗: Assessment at end of year 2 of intervention

Three pairwise comparisons between usual care (TAU), AD+CHW, and AD for number of participants who are abstinent (defined as 7-day point prevalence tobacco abstinence confirmed with an expired CO of 5 ppm or less) at the intervention year 2 assessment. The investigators hypothesize that (1) those who receive AD+CHW will demonstrate higher rates of tobacco abstinence than those who receive TAU, (2) those who receive AD will demonstrate higher rates of tobacco abstinence than those who received TAU, and (3) those who receive AD+CHW will demonstrate higher rates of tobacco abstinence than those who received AD.

次要结局

  • Number of Participants Who Use of Any First Line, Evidence-based TUD Medication at the Intervention Year 1 or 2 Assessment in Cohort 1(Any use over assessments for years 1 or 2 of intervention)
  • Number of Participants Who Use Varenicline at the Intervention Year 1 or 2 Assessments in Cohorts 1 and 2(Any use over assessments for years 1 or 2 of intervention)
  • Health-related Quality of Life Single-item Assessment at the Intervention Year 2 Assessment in Cohorts 1 and 2(Assessment at end of year 2 of intervention)
  • Effect of Varenicline Use on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohorts 1 and 2(Assessment at end of year 2 of intervention)
  • Number of Participants Who Use Varenicline at the Intervention Year 1 or 2 Assessment in Cohort 1(Any use over assessments for years 1 or 2 of intervention)
  • Effect of Varenicline Use on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohort 1(Assessment at end of year 2 of intervention)
  • Number of Participants Who Are Abstinent at the Intervention Year 2 Assessment in Cohorts 1 and 2(Assessment at end of year 2 of intervention)
  • Number of Participants Who Use of Any First Line, Evidence-based TUD Medication at the Intervention Year 1 or 2 Assessment in Cohorts 1 and 2(Any use over assessments for years 1 or 2 of intervention)
  • Effect of Use of Any TUD Medication on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohorts 1 and 2(Assessment at end of year 2 of intervention)
  • Effect of Use of Any TUD Medication on Number of Participants Who Are Abstinence at the Intervention Year 2 Assessment in Cohort 1(Assessment at end of year 2 of intervention)
  • Health-related Quality of Life Single-item Assessment at the Intervention Year 2 Assessment in Cohort 1(Assessment at end of year 2 of intervention)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

A. Eden Evins

Director, Center for Addiction Medicine

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验

Integrated Smoking Cessation Treatment for Smokers... | 临床试验